Latest News and Press Releases

Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 ...

BOULDER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing...

BOULDER, Colo., July 20, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing...

BOULDER, Colo., July 06, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by...

BOULDER, Colo., July 01, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by...

– BBI-02 is a potential first-in-class, oral DYRK1A inhibitor with strong preclinical validation and broad potential to treat debilitating autoimmune and inflammatory diseases – – Topline...

Completed sale of sofpironium bromide to Botanix Pharmaceuticals for up to $9 million in upfront and potential near-term regulatory milestone payments, $168 million in potential future regulatory and...

BOULDER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by...

Meeting adjourned to May 17, 2022 at 10 a.m. MT Brickell encourages all stockholders of record on March 7, 2022 who have not yet voted to do so by 11:59 p.m. Eastern Time on May 16, 2022 BOULDER,...

Deal includes up to $9 million in upfront and potential near-term regulatory milestone payments, $168 million in potential future regulatory and sales milestone payments, plus tiered earn out payments...